Receptos to Present at Leerink Global Healthcare Conference
10 February 2015 - 12:00AM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, today announced that Faheem Hasnain, its
President and Chief Executive Officer, will be presenting at the
Leerink Global Healthcare Conference at the Waldorf Astoria hotel
in New York City. The presentation is scheduled as a fireside chat
on Thursday, February 12 at 1:25 p.m. Eastern Time.
About Receptos
Receptos is a biopharmaceutical company developing
therapeutic candidates for the treatment of immune and metabolic
diseases. The Company's lead program, RPC1063, is a sphingosine
1-phosphate 1 and 5 receptor small molecule modulator in
development for immune indications including RMS and
IBD. Patents supporting RPC1063 were exclusively licensed to
Receptos from The Scripps Research
Institute (TSRI). The Company is also developing RPC4046,
an anti-interleukin-13 (IL-13) antibody for eosinophilic
esophagitis (EoE), an allergic/immune-mediated orphan disease.
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
More News Articles